Guido Oelkers

All filings by Guido Oelkers on record concern Swedish Orphan Biovitrum AB (publ), in the capacity of chief executive. We count 14 filings; the first trade dates from 27 October 2025 and the latest from 31 July 2026.

The open-market side counts 8 purchases for €13.8M alongside 5 sales for €19.9M. Taken together, the sales exceed the purchases by €6.0M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant. 2026 to date brings 5 purchases and 5 sales.

The median purchase comes to €1.9M. Scaled by market value, the purchases weigh a median 0.014% of market cap (sample: 8 purchases). Of 6 purchases, 6 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 3 purchases show a median change of +5.4%, with the price up in 100% of them. Past outcomes like these are no guarantee of what comes next.

The record was last updated on 31 July 2026 with an open-market purchase (€1.7M) in Swedish Orphan Biovitrum AB (publ). Typically, a trade is published a median of 1 day after it takes place. The legal deadline for notifying a trade is three business days (MAR article 19). This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.